{ "schemaVersion": "2.1", "datasetVersion": "2026-09-11.1", "generatedAt": "2026-09-11", "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.", "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.", "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.", "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.", "changeLogPath": "/corrections#correction-ledger", "contactPath": "/corrections", "dataset": "peptide-evidence-checker-record", "canonicalPath": "/peptides/tirzepatide", "canonicalUrl": "https://thepeptidefield.com/peptides/tirzepatide", "record": { "slug": "tirzepatide", "name": "Tirzepatide", "className": "GIP and GLP-1 receptor agonist", "sequenceLabel": "39 amino acids · modified peptide", "tier": "Established", "statusLine": "Some FDA-approved tirzepatide products exist for specific uses", "profile": { "humanOutcomes": { "level": "Strong", "note": "Large randomized studies support blood-sugar, weight, and heart-risk results in specific groups." }, "humanPharmacology": { "level": "Strong", "note": "Studies have described how approved products enter and affect the body in detail." }, "safetyKnowledge": { "level": "Strong", "note": "Current product labels describe boxed warnings, contraindications, precautions, and adverse reactions." }, "productCertainty": { "level": "Strong", "note": "Confidence is high for a genuine approved product. It does not automatically apply to every compounded or counterfeit version." } }, "oneLine": "Some FDA-approved tirzepatide products have evidence for blood-sugar, weight, sleep-apnea, or heart-risk outcomes in specific groups of people. Each product's current label sets its uses and safety information.", "reviewedAt": "August 30, 2026", "whatItIs": "Yes. Tirzepatide is a modified peptide based on a body signal called GIP. Its peptide chain has 39 amino acids. It also has a fat-like side group attached through a linker. This group helps it bind to albumin, a protein in blood. This helps tirzepatide stay in the body longer. Tirzepatide is the active ingredient in Mounjaro and Zepbound. Approval applies to a specific product, use, finished form, and current label. It does not apply to every item sold under the name tirzepatide.", "whatWeKnow": "The studies looked at specific groups of people for set periods. FDA-reviewed labels and large randomized trials support blood-sugar, weight, and heart and blood-vessel outcomes in these groups. Mounjaro also has an FDA-approved heart-risk use. It can lower the risk of death from heart or blood-vessel disease, a nonfatal heart attack, or a nonfatal stroke. This use is for adults with type 2 diabetes who are at high risk. SURPASS-2 studied adults with type 2 diabetes. SURMOUNT-1 studied adults with obesity, or overweight with a related condition, who did not have diabetes. These study groups, comparisons, outcomes, and time periods set the limits of each result.", "whatWeDoNotKnow": "The evidence does not show that tirzepatide gives everyone the same result. It does not establish a universal “metabolic reset,” longer life, or better athletic performance. Evidence for approved medicines does not make compounded, counterfeit, or research-labeled products equivalent to those medicines.", "safetyBoundary": "Current prescribing information contains a boxed warning and important contraindications, warnings, and precautions. This guide does not tell you whether a product is right for you. It does not recommend a product or give dosing or dose-change instructions.", "claims": [ { "claim": "“Tirzepatide has established human outcome evidence for defined metabolic indications.”", "verdict": "Supported with scope", "explanation": "Approved product labels and large randomized trials support specific blood-sugar, weight, and cardiovascular outcomes in defined populations.", "category": "Clinical outcomes", "evidenceBasis": "Randomized human outcomes", "scope": "The labeled and trial populations, outcomes, comparators, and durations for Mounjaro and Zepbound. Mounjaro's heart-risk use was approved August 27, 2026.", "sourceUrls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215866Orig1s044,215866Orig1s045ltr.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s041ltr.pdf", "https://pubmed.ncbi.nlm.nih.gov/35658024/", "https://pubmed.ncbi.nlm.nih.gov/34170647/" ] }, { "claim": "“Trial results prove tirzepatide works the same way for everyone and should be used indefinitely.”", "verdict": "Not established", "explanation": "Trials estimate effects for studied populations and durations. They do not establish an identical individual response or a universal treatment duration.", "category": "Clinical outcomes", "evidenceBasis": "Randomized human outcomes", "scope": "The defined populations and follow-up durations in SURMOUNT-1 and SURPASS-2.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/35658024/", "https://pubmed.ncbi.nlm.nih.gov/34170647/" ] }, { "claim": "“Compounded tirzepatide is equivalent to an approved product.”", "verdict": "Misleading", "explanation": "FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, so evidence for an approved product cannot simply be transferred.", "category": "Product equivalence", "evidenceBasis": "Regulatory or product record", "scope": "Compounded or otherwise unapproved tirzepatide compared with approved Mounjaro or Zepbound.", "sourceUrls": [ "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" ] } ], "sources": [ { "label": "MOUNJARO (tirzepatide) prescribing information, revised January 2026", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf", "kind": "Drug label", "accessedAt": "2026-08-30", "year": 2026 }, { "label": "ZEPBOUND (tirzepatide) prescribing information, revised February 2026", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf", "kind": "Drug label", "accessedAt": "2026-08-30", "year": 2026 }, { "label": "FDA approval letter: Mounjaro heart-risk indication, August 27, 2026", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215866Orig1s044,215866Orig1s045ltr.pdf", "kind": "FDA review", "accessedAt": "2026-08-30", "year": 2026 }, { "label": "FDA supplement letter: Zepbound cardiovascular-trial information, August 26, 2026", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s041ltr.pdf", "kind": "FDA review", "accessedAt": "2026-08-30", "year": 2026 }, { "label": "FDA review: tirzepatide's 39-amino-acid structure", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000SumR.pdf", "kind": "FDA review", "accessedAt": "2026-08-30", "year": 2022 }, { "label": "Tirzepatide once weekly for the treatment of obesity", "publisher": "PubMed · New England Journal of Medicine", "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/", "kind": "Randomized trial", "accessedAt": "2026-08-30", "year": 2022 }, { "label": "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes", "publisher": "PubMed · New England Journal of Medicine", "url": "https://pubmed.ncbi.nlm.nih.gov/34170647/", "kind": "Randomized trial", "accessedAt": "2026-08-30", "year": 2021 }, { "label": "FDA’s concerns with unapproved GLP-1 drugs used for weight loss", "publisher": "U.S. Food and Drug Administration", "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss", "kind": "Regulatory", "accessedAt": "2026-08-30", "year": 2026 } ], "aliases": [ "Mounjaro", "Zepbound", "GIP/GLP-1 agonist" ], "family": "Metabolic peptide medicines", "evidenceContext": "Approved human outcomes", "productContext": "Mounjaro and Zepbound are distinct approved products. Their evidence and labels do not make every compounded or research-labeled tirzepatide product equivalent.", "approvedProducts": [ "Mounjaro", "Zepbound" ], "productRecords": [ { "name": "Mounjaro", "formulation": "Injection", "route": "Subcutaneous", "indicationScope": "Blood-sugar control in defined type 2 diabetes populations. FDA approved a heart-risk reduction use for certain adults with type 2 diabetes on August 27, 2026.", "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf", "labelRevision": "January 2026 published label; August 27, 2026 supplement approval; revised label not yet posted" }, { "name": "Zepbound", "formulation": "Injection", "route": "Subcutaneous", "indicationScope": "Long-term weight management and moderate-to-severe obstructive sleep apnea in defined adults with obesity. An August 26, 2026 FDA supplement added cardiovascular-trial information, not a new use.", "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf", "labelRevision": "February 2026 published label; August 26, 2026 supplement letter" } ], "indications": [ "Type 2 diabetes for labeled populations", "Lowering the risk of heart attack, stroke, or cardiovascular death in certain high-risk adults with type 2 diabetes under the August 27, 2026 Mounjaro approval", "Chronic weight management for labeled populations", "Moderate-to-severe obstructive sleep apnea in adults with obesity under the current Zepbound label" ], "reviewedAtISO": "2026-08-30", "reviewHistory": [ { "date": "2026-08-30", "note": "Updated Mounjaro and Zepbound label records, added the Mounjaro heart-risk approval and Zepbound supplement, and linked the FDA structure review." }, { "date": "2026-07-23", "note": "Expanded product, outcome, and unapproved-version boundaries." } ], "antiDoping": null, "antiDopingReview": { "status": "Not assessed", "detail": "This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.", "sourceUrl": null, "reviewedAtISO": "2026-07-23" }, "relatedSlugs": [ "semaglutide", "liraglutide", "retatrutide" ] } }